The Metabolic Activation of Sofosbuvir Is Impaired in an Experimental Model of NAFLD.

Gabbia, Daniela; Roverso, Marco; Sarcognato, Samantha; Zanotto, Ilaria; Ferri, Nicola; Russo, Francesco Paolo; Guido, Maria; Bogialli, Sara; De Martin, Sara

Gabbia, Daniela; Roverso, Marco; Sarcognato, Samantha; Zanotto, Ilaria; Ferri, Nicola; Russo, Francesco Paolo; Guido, Maria; Bogialli, Sara; De Martin, Sara.

Afiliação

Gabbia D; Department of Pharmaceutical and Pharmacological Sciences, University of Padova, 35131 Padova, Italy.
Roverso M; Department of Chemical Sciences, University of Padova, 35131 Padova, Italy.
Sarcognato S; Department of Medicine, University of Padova, 35131 Padova, Italy.
Zanotto I; Department of Pharmaceutical and Pharmacological Sciences, University of Padova, 35131 Padova, Italy.
Ferri N; Department of Medicine, University of Padova, 35131 Padova, Italy.
Russo FP; Department of Surgery, Oncology and Gastroenterology, University of Padova, 35131 Padova, Italy.
Guido M; Department of Medicine, University of Padova, 35131 Padova, Italy.
Bogialli S; Department of Chemical Sciences, University of Padova, 35131 Padova, Italy.
De Martin S; Department of Pharmaceutical and Pharmacological Sciences, University of Padova, 35131 Padova, Italy.

Biology (Basel) ; 11(5)2022 Apr 30.

Article em En | MEDLINE | ID: mdl-35625421

Palavras-chave

HCV; NAFLD; UMP-CMPK1; drug metabolism; pharmacokinetics; sofosbuvir

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Prognostic_studies Idioma: En Revista: Biology (Basel) Ano de publicação: 2022 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google